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Abstract
Background: Lipids can act as signaling molecules, activating intracellular and membrane-associated receptors to regulate
physiological functions. To understand how a newly discovered signaling lipid functions, it is necessary to identify and
characterize the enzymes involved in their production and inactivation. The signaling lipid N-palmitoylethanolamine (PEA) is
known to activate intracellular and membrane-associated receptors and regulate physiological functions, but little is known
about the enzymes involved in its production and inactivation.
Principal Findings: Here we show that Saccharomyces cerevisiae produce and inactivate PEA, suggesting that genetic
manipulations of this lower eukaryote may be used to identify the enzymes involved in PEA metabolism. Accordingly, using
single gene deletion mutants, we identified yeast genes that control PEA metabolism, including SPO14 (a yeast homologue
of the mammalian phospholipase D) that controls PEA production and YJU3 (a yeast homologue of the mammalian
monoacylglycerol lipase) that controls PEA inactivation. We also found that PEA metabolism is affected by heterologous
expression of two mammalian proteins involved in neurodegenerative diseases, namely huntingtin and a-synuclein.
Significance: Together these findings show that forward and reverse genetics in S. cerevisiae can be used to identify
proteins involved in PEA production and inactivation, and suggest that mutated proteins causing neurodegenerative
diseases might affect the metabolism of this important signaling lipid.
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Introduction
Lipids are the building blocks of cell membranes, and their
turnover is regulated by specific enzymes, including lipases and
acyltransferases. Stimuli that regulate the activity of these enzymes
may transiently change lipid turnover and cause the release of
specific lipids from cell membranes. Released lipids may then
activate intracellular and membrane-associated receptors, and
thus act as second messengers, transmitters and hormones. The
biological actions of released lipids are terminated by hydrolysis or
chemical modification. Thus, since the biological action of
released lipids depends on their rate of production and
inactivation, the enzymatic steps involved in these processes must
be fully appreciated to understand their signaling function.
The endocannabinoids (eCBs) N-arachidonoylethanolamine
(anandamide) and 2-arachidonoylglycerol (2-AG) are signaling
lipids that act through membrane-associated cannabinoid recep-
tors and regulate neurotransmission, inflammation, and other
physiopathological functions [1]. Anandamide is an N-acyletha-
nolamine (N-AE) and 2-AG is a glycerolacylester. Both contain a
C20:4 acyl chain, but their respective polar groups impinge
distinct pharmacological profiles at cannabinoid receptors [2].
PEA, a signaling lipid of the N-AE family, contains a C16:0 acyl
chain and acts on its own membrane-associated and intracellular
receptors, including Gpr55 and PPARa [3,4]. Thus, while
anandamide, 2-AG, and PEA are structurally related, these lipids
possess different bioactivities, and unraveling their respective
functions will require a better understanding of the molecular
mechanisms controlling their production and inactivation.
Anandamide, 2-AG, and PEA may be independently released
from cell membranes [5,6], suggesting that independent enzymes
and molecular mechanisms control their production. To date, at
least four enzymes have been implicated in anandamide
production: a subtype of phospholipase D (Nape-Pld), phospho-
lipase C (Plc), phosphatase (Ptpn22) and hydrolase (a/b-hydrolase
4) [7–9]. Four enzymes have been implicated in 2-AG production:
Plc-b, a- and b- diacylglycerol lipase, and lyso-Plc [10–13]. Only
one enzyme has been implicated in PEA production: Nape-Pld
[14]. Thus, little is known about PEA production.
Anandamide is predominantly inactivated by fatty acid amide
hydrolase (Faah) and, under certain conditions, by cyclooxygen-
ase, lipooxygenase, and N-acylethanolamine-hydrolyzing acid
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lipase (Mgl), triacylglycerol lipase, cyclooxygenases, lipooxy-
genases, and the newly identified a/b-hydrolase 6, a/b-hydrolase
12 (Abhd12), and Neuropathy target esterase [20–25]. PEA is
inactivated by Faah and Naaa [16,26–27] and possibly by a
unidentified enzyme expressed by microglial cells [28]. Thus, at
least one enzyme that inactivates PEA remains to be identified at
the molecular level.
Saccharomyces cerevisiae has been extensively used as genetic tool to
dissect metabolic pathways, including those involved in lipid
production and inactivation. Although these cells have no genes
encoding for receptors activated by anandamide and 2-AG, they
express Oaf1/Pip2, a functional homologue of PPARa activated
by PEA [29]. Furthermore, S. cerevisiae expresses enzymes closely
related to those which produce and inactivate N-AEs and
glycerolacylesters in mammalian cells (Table 1). Thus, it is possible
that these lower eukaryotes may also produce and inactivate
anandamide, 2-AG and PEA. If so, genetic screens could be used
to systematically identify genes controlling their production and
inactivation.
Here we addressed these possibilities by determining if S.
cerevisiae produce anandamide, 2-AG and PEA (as well as several
additional related N-AEs). We also tested whether single gene
deletions or heterologous expression of mammalian proteins
affects the production and inactivation of such signaling lipids.
Results
We used chemical ionization gas chromatography mass
spectrometry (CI-GC-MS) to determine if yeast produce ananda-
mide, 2-AG, PEA, as well as several other bioactive N-AEs:
stearoylethanolamide (SEA), oleoylethanolamide (OEA), homo-c-
linolenoylethanolamide (HEA) and docosatetraenoylethanolamide
(DEA). SEA acts through an unknown receptor, OEA acts through
PPARa, while HEA and DEA are closely related to anandamide
and also act on CB1 receptors [30–34].
Yeast Produce PEA
To identify and quantify the levels of these lipids, we spiked
yeast homogenates with corresponding deuterated standards and
performed isotope-dilution quantifications [35]. Since deuterated
standards contain trace amounts of the lipid itself (typically a few
percent), we first determined the amount of yeast homogenate
required to generate an ion current ratio that is statistically greater
than that generated by the standards alone. Yeast cells were grown
to saturation and homogenized, and the total protein concentra-
tions quantified. Total homogenate (0.5, 1, and 3 mg of total
protein) was chloroform-extracted in the presence of 200 pmol of
the deuterated standards and analyzed by isotope-dilution CI-GC-
MS. We found that the ion current ratios of PEA/[
2H4]-PEA
generated by 1 and 3 mg of yeast homogenates were the only ones
statistically greater than those generated by standards alone
(Figure 1). Denser samples led to chromatography overload,
precluding quantitative analysis. Conversion of the ratios showed
that yeast produce 0.65 pmol of PEA per mg of protein, well within
the range generated in mammalian tissue [35].
The Lipase Spo4 Contributes to PEA Production
In the next series of experiments, we used a candidate gene
approach and selected ten yeast strains with single gene deletions
for various lipases and acyltransferases (Table 1), and determined
the effects of these mutations on PEA production compared to
wild type yeast. Figure 2 shows that PEA production was reduced
by 46% in spo14D cells, which lack a phospholipase D-like activity,
and that this reduction was fully rescued when this gene was
reintroduced. None of the other mutations affected PEA levels
(Figure S1). These results suggest that the phospholipase D-like
activity of Spo14 is responsible for producing PEA in yeast.
Yeast Hydrolyze PEA
Next we assessed the ability of yeast to inactivate PEA. Indeed,
yeast homogenates hydrolyzed [
3H]-PEA in a concentration- and
time-dependent manner, yielding a specific activity of
5.0610
23 pmol/min/mg of protein that reached saturation when
using 100 mg of protein (Figure 3A and 3B). To ascertain that a
protein was responsible for PEA hydrolysis, we subjected yeast
homogenates to heat-induced denaturation. Boiling or autoclaving
these samples reduced hydrolysis by only ,50% (Figure 3C). Since
some enzymes produced by lower organisms are highly resistant to
heat-induced denaturation [36], we also microwaved the homog-
enates. This regimen also reduced [
3H]-PEA hydrolysis by ,50%
(Figure 3C). As positive control for these experiments, we used
homogenates of human embryonic kidney cells HEK293 cells.
These cells hydrolyzed [
3H]-PEA in a protein-concentration and
time-dependent manner, yielding a specific activity of
3.9610
22 pmol/min/mg of protein that reached saturation when
Table 1. Humans orthologs of yeast genes coding for selected proteins involved in lipid metabolism in yeast.
Yeast gene Putative function in yeast Human gene Protein sequence identity
LRO1 Acyltransferase LyPla3 31%
PLB1 Phospholipase B Pla2 24%
PLB2 Phospholipase B Pla2 26%
PLB3 Phospholipase B Pla2 24%
PLC1 Phospholipase C Plcd4 31%
ISC1 Phospholipase C Smpd2 28%
SPO14 Phospholipase D Pld1 44%
YJU3 Serine hydrolase activity Mgl 24%
AMD2 Amidase Faah 27%
FSH1 Serine hydrolase Ovca2 27%
The table shows example of yeasts gene coding for proteins involved in lipid metabolism. Their human hortolog are listed with the sequence identity between the yeast
and the human protein.
doi:10.1371/journal.pone.0005942.t001
PEA Metabolism in Yeast
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homogenates were boiled, autoclaved, or microwaved (Figure 3F).
To determine whether both the heat-sensitive and heat-resistant
PEA hydrolysis in yeast were due to proteins, we treated the yeast
homogenates with trypsin, a-chemotrypsin, and a protease from
Streptomyces griseus. Figure 3G shows that both a-chemotrypsin and
the Streptomyces griseus protease reduced the entire PEA hydrolysis
activity by 96% and 99%, respectively, showing that both heat-
sensitive and heat-resistant activities are due to proteins.
A Serine Hydrolase Distinct From FAAH Hydrolyzes PEA
We performed an initial biochemical characterization of the
enzymatic activity responsible for [
3H]-PEA hydrolysis. In yeast,
unlabelled PEA inhibited this activity in dose-dependent manner,
reaching ,50% inhibition at 100 mM PEA (Figure 4A). In
HEK293 homogenates, unlabelled PEA competed for [
3H]-PEA
hydrolysis, reaching 50% inhibition at 3.1 mM and 90% inhibition
at 100 mM PEA (Figure 4D). [
3H]-PEA hydrolysis by yeast
homogenates was marginally affected by changes in pH
(Figure 4B), suggesting that several yeast enzymes can hydrolyze
PEA, each at their optimal pH value. In contrast, hydrolysis by
HEK293 cells was clearly pH dependent, increasing by 10-fold
between pH 3 and 9 (Figure 4E), suggesting hydrolysis by a single
enzyme with optimal activity at pH 9. One such enzyme is Faah
[26,27,37].
Three chemically distinct inhibitors (PMSF, MAFP, and
URB597) were tested on PEA hydrolysis by both yeast and
HEK293 cell homogenates. While both PMSF and URB597 were
inactive on [
3H]-PEA hydrolysis by yeast homogenates, MAFP at
300 nM inhibited 50% of this activity, suggesting the involvement
of a serine hydrolase (Figure 4C). In HEK293 cells homogenates,
PMSF and MAFP partially inhibited [
3H]-PEA hydrolysis, leaving
approximately 30% of the activity intact, while URB597 fully
inhibited [
3H]-PEA hydrolysis (Figure 4F). These results suggest
that the enzyme(s) responsible for PEA hydrolysis in yeast is/are
most likely a serine hydrolase(s) distinct from Faah, whereas Faah
is likely the main enzyme responsible for PEA hydrolysis in
HEK293 cells.
The Serine Hydrolase Yju3 Contributes to PEA Hydrolysis
When testing the ten yeast strains with single gene mutations
that we had selected (Table 1), we found that PEA hydrolysis was
reduced by 49% in yju3D, a strain that lacks a serine hydrolase
orthologous to the mammalian MGL (Figure 5A). This reduction
in activity was not only rescued when the YJU3 gene was
reintroduced, but PEA hydrolysis was actually greatly increased
(Figure 5A). This increased PEA hydrolyzing activity exhibited by
Yju3-bearing yeast strains was reduced by 57% by MAFP and by
Figure 1. Yeast produces PEA. Increasing amounts of yeast homogenate (0, 0.5, 1, and 3 mg of protein per sample) were analyzed by CI-GC-MS
and the non-deuterated/deuterated ratios determined using 200 pmol of [
2H5]-2-AG and [
2H4]-N-AEs standards. Values are the mean6SEM of three
to four independent experiments, performed in duplicate, and demonstrate that only PEA is reliably detected in yeast homogenates using this
method. * P,0.05 and ** P,0.01 compared to the ratios obtained in the absence of yeast homogenate (ANOVA one-way, Dunnett’s post test).
doi:10.1371/journal.pone.0005942.g001
Figure 2. Spo14 is involved in PEA production. PEA levels in
SPO14 gene-deleted yeast strain (spo14D) are compared to wild-type
strain (WT), and to the PEA levels measured in a SPO14 gene-deleted
yeast strain in which an SPO14 ORF was reintroduced (SPO14 ORF).
Values are the mean6SEM of three experiments, performed in
duplicate. ** P,0.01 compared to PEA levels obtained for WT yeast
(ANOVA one-way, Dunnett’s post test).
doi:10.1371/journal.pone.0005942.g002
PEA Metabolism in Yeast
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PLoS ONE | www.plosone.org 4 June 2009 | Volume 4 | Issue 6 | e5942Figure 3. Initial characterization of PEA Hydrolysis by Yeast Homogenates. [
3H]-PEA hydrolysis by yeast homogenates is protein
concentration-dependent (A; 20 min incubation) and time-dependent (B; 60 mg of protein). Similarly, HEK293 cells homogenates hydrolyze [
3H]-PEA
in a protein concentration- (D; 20 min incubation) and time-dependent manner (E; 20 mg of protein). When submitted to denaturing conditions such
as heat or microwaves, <50% of the yeast PEA-hydrolytic activity (C) and <100% of the HEK293 cells homogenate activity (F) are lost, suggesting that
part of the hydrolytic activity in yeast in heat-resistant. [
3H]-PEA hydrolysis is greatly reduced in yeast homogenates incubated with a-chymotrypsin
or with protease from Streptomyces griseus (G) confirming the enzymatic nature of the entire PEA hydrolysis. Data points are the mean6SEM of three
to four experiments done in duplicate. ** P,0.01 compared to control homogenates (ANOVA one-way, Dunnett’s post test).
doi:10.1371/journal.pone.0005942.g003
Figure 4. Further characterization of PEA Hydrolysis by Yeast Homogenates. The effect of increasing concentrations of PEA on [
3H]-PEA
hydrolysis by yeast (A) and HEK293 cells (D) homogenates and the influence of the pH on [
3H]-PEA hydrolysis by yeast (B) and HEK293 cells (E)
homogenates were determined. The following buffers were used (100 mM): NaAcetate (pH 3–5), HEPES (pH 6–7), Tris (pH 8–9) and Na2B4O7 (pH 10–
11). The serine hydrolase inhibitors PMSF and MAFP and the specific Faah inhibitor URB597 differentially affected [
3H]-PEA hydrolysis by yeast (C) and
HEK cells (F) homogenates. Data points represent the mean6SEM of 3 to 5 experiments performed in duplicate and are expressed as percentage of
control. * P,0.05 and ** P,0.01 compared to control homogenates (ANOVA one-way, Dunnett’s post test).
doi:10.1371/journal.pone.0005942.g004
PEA Metabolism in Yeast
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suggesting that the MGL-like activity of Yju3 is responsible for the
heat-sensitive PEA hydrolyzing activity expressed by yeast.
Interestingly, plc1D and isc1D, two strains deficient in Plc-like
activity, led to a small, but significant increase in PEA hydrolysis,
suggesting compensatory mechanisms (Figure S1). Furthermore,
genetic deletion of AMD2, a yeast homologue of Faah, did not
affect PEA production or inactivation (Figure S1), which
strengthens the conclusion that PEA is hydrolyzed by a yeast
enzyme without Faah-like activity.
Mutant Huntingtin and a-Synuclein Affect PEA
Production and Inactivation
Because several mammalian proteins involved in the pathogen-
esis of neurodegenerative diseases are known to affect lipid
metabolism [38], and several neuropathologies lead to changes in
PEA levels in brain [39], we expressed mutant huntingtin (Htt)
fragments and a-synuclein in yeast and assessed their effect on
PEA production and inactivation.
Htt fragments containing 25 and 103 polyglutamine repeats
(25Q and 103Q), as well as a-synuclein, each increased by ,2 fold
the levels of PEA (Figure 6A–C), whereas the empty vector had no
significant effect (data not shown). To determine if this increase in
PEA production involves Spo14, we expressed Htt fragments and
a-synuclein in the spo14D strain, and measured PEA levels.
Remarkably, PEA levels were also increased by ,2 fold by these
pathogenic fragments and proteins in this strain (Figure 6A–C),
suggesting that they induce the expression of another PEA
producing enzyme.
With regard to PEA hydrolysis, Htt25Q reduced it by 65%,
Htt103Q had a small (17%), but significant effect, and a-synuclein
reduced this activity by 32% (Figure 7A–C). The empty vector had
no significant effect (data not shown). To determine if this decrease
in PEA hydrolysis involves Yju3, we expressed Htt fragments and
a-synuclein in the yju3D strain. Here too, PEA hydrolysis was
similarly decreased by these pathogenic fragments and proteins
(Figure 7A–C), suggesting that they reduce the expression of
another PEA hydrolyzing enzyme.
Discussion
PEA is a highly bioactive lipid that activates intracellular and
membrane-bound receptors distinct from those activated by eCBs.
The molecular machinery controlling PEA production and
inactivation in mammalian cells is not fully understood [40–43].
Our results show that S. cerevisiae produce and inactivate PEA, and
that this process is significantly altered by single gene deletions or
heterologous expression of mammalian proteins involved in
neurodegenerative diseases. Thus, our findings show that forward
and reverse genetics in yeast can be used to identify the molecular
components that control PEA production and inactivation.
Using CI-GC-MS and isotope-dilution, we demonstrated that S.
cerevisiae produce significant amounts of PEA, a lipid that contains
a C16:0 acyl chain, while not producing detectable amounts of
anandamide, 2-AG, OEA, SEA, HEA, and DEA, all of which
contain acyl chains with more than 16 carbon atoms. Accordingly,
classic studies showed that lower eukaryotes cannot produce fatty-
acid chains containing more than 16 carbon atoms despite the
presence of two enzymes, fatty acid elongase and enoyl reductase,
that are known to lengthen carbon acyl chains [44–46].
The amount of PEA we detected in yeast (650 pmol/g) is
comparable to that in mouse brain (100–500 pmol/g) and
cultured neural cells (1800–2200 pmol/g of protein) (for review
see [35]). However, reliable PEA quantification required only
3 mg of yeast homogenate sample but 30 mg of mouse brain
homogenate [35]. This 10-fold difference suggests that the
polysaccharide wall in yeast is less invasive when analyzing PEA
by CI-GC-MS than the rich lipidic environment of the brain.
PEA is also produced and hydrolyzed by plants, where it is
thought to be a response mechanism to stressors and regulator of
plant growth [47]. PEA was also quantified in Ciona intestinalis and
in leech [48]. Together with our results, these studies show that
PEA is produced by a wide variety of cell types and organisms.
Whether PEA constitutes a building block of yeast membranes or
carries the function of signaling lipid in these lower eukaryotes
remains to be determined. Note that while we do not suggest that
the function of PEA as a signaling lipid in mammalian cells is
conserved in yeast, our data indicate that the basic machinery
involved in its production and inactivation might be conserved,
and therefore yeast constitute an incredibly efficient genetic tool to
dissect the molecular mechanisms involved in PEA metabolism.
Genetic evidence demonstrating the involvement of specific
enzymes in PEA production and inactivation is sparse. To our
knowledge, only two examples have been reported: Nape-Pld,
which affects PEA production, and Faah, which affects PEA
inactivation [14,26]. By screening 10 yeast gene deletion strains,
Figure 5. Yju3 is involved in PEA hydrolysis. [
3H]-PEA hydrolysis in YJU3 gene-deleted yeast strain (yju3D) is compared to wild-type strain (WT),
and to the hydrolysis measured in a YJU3 gene-deleted yeast strain in which an YJU3 ORF was reintroduced (YJU3 ORF) (A). The [
3H]-PEA hydrolysis
found in the Yju3 expressing strain (i.e. YJU3 ORF expressing strain (CTL)) is partially sensitive to MAFP inhibition and sensitive to denaturing
conditions (boiled) (B). Values are the mean6SEM of three experiments performed in duplicate and are expressed as percentage of control. ** P,0.01
compared to control (ANOVA one-way, Dunnett’s post test).
doi:10.1371/journal.pone.0005942.g005
PEA Metabolism in Yeast
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tion in yeast. PEA levels found in BY4741 yeast strains expressing a
25Q and 103Q huntingtin fragment and in yeast strain expressing a-
synuclein (BY4741) were compared to BY4741 strains expressing an
empty vector (dotted line). Similarly PEA levels found in SPO14 gene-
deleted yeast strains expressing the same proteins (spo14D) were
compared to spo14D strains expressing an empty vector (dotted line)
(A–C). Values are the mean6SEM of three to five experiments
performed in duplicate and are expressed as percentage of corre-
sponding control (empty vector expressing BY4741 strain and empty
vector expressing spo14D strain, respectively). ** P,0.05 and ** P,0.01
compared to respective control (unpaired two-tailed Student’s t-test).
doi:10.1371/journal.pone.0005942.g006
Figure 7. Htt fragments and a-synuclein reduce PEA hydrolysis
in yeast. [
3H]-PEA hydrolysis measured in BY4741 yeast strains
expressing a 25Q and 103Q huntingtin fragment and in yeast strain
expressing a-synuclein (BY4741) were compared to BY4741 strains
expressing an empty vector (dotted line). Similarly [
3H]-PEA hydrolysis
found in YJU3 gene-deleted yeast strains expressing the same proteins
(yju3D) were compared to yju3D strains expressing an empty vector
(dotted line) (A–C). Values are the mean6SEM of three to five
experiments performed in duplicate and are expressed as percentage
of corresponding control (empty vector expressing BY4741 strain and
empty vector expressing yju3D strain, respectively). ** P,0.05 and **
P,0.01 compared to respective control (unpaired two-tailed Student’s
t-test).
doi:10.1371/journal.pone.0005942.g007
PEA Metabolism in Yeast
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like activity) and Yju3 (coding for a Mgl-like serine hydrolase
activity). These genes have mammalian orthologs: Spo14 is related
to Pld1 (coding for a phosphatidylcholine-hydrolyzing Pld1), and
Yju3 is related to Mgl (coding for a monoglyceride lipase) and to
some extent to Abhd12 (coding for a serine hydrolase recently
implicated in eCB signaling [25]). The implication of a yeast
homologue of Mgl and Abhd12 in PEA hydrolysis is remarkable
for two reasons. First, it is known that mammalian Mgl does not
hydrolyze PEA [21], suggesting that the mammalian Mgl evolved
so as to preferentially hydrolyze acylesters rather than acylamide.
Second, the substrate specificity of Abhd12 is still unknown, and
our data suggest that this newly discovered serine hydrolase might
use PEA as substrate and thus be involved in its inactivation in
mammalian cells.
Approximately 50% of the PEA hydrolysis expressed by yeast is
resistant to heat and microwave inactivation, but is fully blocked
by enzymatic digestion. This result agrees with the fact that
enzymes resistant to heat-induced denaturation are expressed by
some lower organisms [36]. While the identity of this heat-resistant
enzyme expressed by yeast remains to be determined, our results
already suggest that it is unlikely to be a serine hydrolyze, since it is
insensitive to the broad serine-hydrolase inhibitor MAFP.
We found that heterologous expression of huntingtin fragments
25Q and 103Q in yeast increased PEA level by ,2 fold, showing
that the ability of huntingtin to control PEA levels does not depend
on the length of the polyglutamine repeat that determines the age
of onset of Huntington’s disease. Considering the proposed role of
huntingtin in the regulation of gene expression [49], this result
suggests that increased PEA levels measured here might not be due
to a direct involvement of huntingtin in PEA metabolism, but
rather due to huntingtin-mediated impairment of transcription of
key molecular steps controlling PEA levels (e.g. increased
expression of enzymes producing PEA or decreased expression
of enzymes inactivating PEA) [50]. We also found that a-synuclein
expression increased PEA levels by ,2 fold, suggesting that the
metabolism of this signaling lipid might also be impaired in
patients with Parkinson’s disease carrying this mutation, as well as
mice models carrying this mutation. To our knowledge, no such
measurement has been reported, even though a-synuclein is
known to affect lipid metabolism [51,38].
The molecular steps occurring between the presence of
huntingtin and a-synuclein in yeast, and a change in PEA
metabolism remain to be determined, since performing these
experiments in yeast strains lacking Spo14 and Yju3 did not
prevent the effects of these pathogenic proteins, suggesting that
they regulate the expression of other proteins. Here, two points
can be made. First, it is unlikely that the increase in PEA levels
induced by Htt25Q, Htt103Q and a-synuclein results from the
down-regulation of a PEA inactivating enzymes, since we found
that the genetic mutation of YJU3 leads to a 49% reduction in
PEA hydrolysis without increasing PEA levels (compare Fig 5a and
Figure S1). Second, the molecular mechanism involved in these
changes in PEA metabolism could be dissected out by using
combinations of the forward and reverse yeast genetic approaches
described here.
In summary, identifying the molecular steps that control the
production and inactivation of signaling lipids is essential for
understanding their biological functions and for developing new
therapeutic approaches. We found that S. cerevisiae produce and
inactivate PEA, and identified several yeast genes involved in its
production and inactivation. PEA metabolism in S. cerevisiae was
affected by heterologous expression of mammalian proteins
involved in Huntington’s disease and Parkinson’s disease,
suggesting that PEA signaling is affected in those conditions.
Thus, our results provide proof-of-concept for the use of reverse
and forward yeast genetics to gain a genome-wide understanding
of the molecular steps in PEA metabolism.
Materials and Methods
Materials
All solvents were of analytical grade. URB597, MAFP, 2-AG,
and [
2H5]-2-AG were from Cayman Chemical (Ann Arbor, MI),
PMSF, trypsin, chemotrypsin, and Streptomyces griseus proteases
were from Sigma (St Louis, MO). [
3H]-PEA (radioactively labeled
on the ethanolamine) was from American Radiolabeled Chemicals
(St. Louis, MO) and the NIDA drug supply system. N-AEs and
[
2H4]-N-AEs were synthesized in our laboratory as previously
described [35]. Briefly, acyl chlorides were mixed in dry CHCl3
with ethanolamine or [
2H4]-ethanolamine, and vigorously mixed
at room temperature for 30 min. The resulting solutions were
extracted three times with water (GC-MS grade) and the organic
layers dried under nitrogen to afford the N-AEs and [
2H4]-N-AEs,
all of which were subsequently purified by solid-phase extraction.
The nature and purity of the N-AEs and [
2H4]-N-AEs were
confirmed by TLC and GC-MS.
Yeast Culture and Homogenate Preparation
Wild-type S. cerevisiae cells and mutated yeast strains MATa
(BY4741) were maintained on YPD Petri dishes. Some wild-type
yeast were transformed with pYES2-Htt25Q-GFP5, pYES2-
Htt103Q-GFP5 or pYES2-a-synuclein-GFP5 using the lithium
acetate method and were maintained on plates containing
synthetic complete media lacking uracil (SC-Ura). Similar
transformations were performed in spo14D and yju3D yeast strains.
Htt103Q is a galactose (GAL)-inducible, FLAG- and GFP-tagged
construct encoding the first 17 amino acids of Htt fused to a polyQ
tract of 103 glutamines, longer than the threshold for Huntington
disease pathogenesis. The spo14D and yju3D yeast strains were also
transformed with plasmids that express Spo14 and Yju3 (or empty
vector), respectively, for reintroduction of the gene of interest. All
these expressing strains were grown in SC-Ura media containing
raffinose, instead of glucose, and that media replaced by galactose
containing media for an overnight induction. Respective yeast
strains grown at saturation were recovered by centrifugation
(13006g, 10 min, 4uC) and rinsed twice with PBS. Aliquots were
then added to glass vials containing glass beads (Sigma, St Louis,
MO) and vigorously shaken for 15 min (4uC), allowing for through
cell disruption, before determining protein content.
HEK Cell Culture and Homogenate Preparation
HEK cells were expanded in MEM supplemented with 1 mM
glutamine, 10 mM HEPES, 10 mM NaHCO3, 100 U/mL
penicillin, 100 mg/mL streptomycin and 10% FBS. Confluent
cells in 100 mm dishes were rinsed once with PBS, lysed in 1 ml of
ice-cold Hepes (250 mM) – Sucrose (10 mM) buffer (pH 7.4) and
homogenized on ice using a Dounce tissue homogenizer.
eCBs and N-AEs Quantification by GC/MS
eCBs and N-AEs amounts in yeast were quantified as previously
described [35]. Briefly, freshly obtained yeast homogenates (3 mg
of protein in PBS buffer, except for Figure 1) were added to 10 ml
of ice-cold CHCl3 containing deuterated standards (200 pmol of
[
2H4]-anandamide, [
2H4]-DEA, [
2H4]-HEA, [
2H4]-OEA, [
2H4]-
PEA, [
2H4]-SEA and [
2H5]-2-AG). Folch extraction was per-
formed by adding ice-cold CH3OH (5 ml) and PBS (total volume
of 5 ml). The mixture was vigorously shaken and sonicated (5 min
PEA Metabolism in Yeast
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(5 min at 8006g), the organic phase was recovered into a glass vial
and dried under nitrogen. The residue was dissolved in CHCl3
(2 ml) and partially purified by solid-phase extraction using silica
and ethyl acetate-acetone (1:1) as eluent. Eluates were then dried
under nitrogen, derivatized using BSTFA (50 min, 55uC), and
stored in hexane at 220uC until CI-GC/MS analysis. Calibration
curves for eCBs and N-AEs quantification were built following the
same procedure (except for the absence of yeast homogenate).
[
3H]-PEA Hydrolysis
Yeast homogenates (60 mg of protein in 400 ml) or HEK cells
homogenate (20 mg of protein in 400 ml) were added to silanized
glass tubes containing either 0.5 ml of drug in DMSO or DMSO
alone (0.1%, control). Hydrolysis was initiated by the addition of
[
3H]-PEA (100 ml, 70,000 dpm) in Tris.HCl containing 0.1% fatty
acid-free BSA. All additions were done using silanized pipette tips.
Tubes were incubated for 20 min in a shaking water bath at 37uC.
Tubes containing buffer only were used as control for chemical
hydrolysis (blank), the value of which was systematically subtract-
ed. Reactions were stopped by the addition of 2 ml of ice-cold
CH3OH:CHCl3 (1:1) and the hydrophilic products of the
hydrolysis extracted by vigorous mixing and subsequent centrifu-
gation at 8006g (10 min). One ml of the upper layer was
recovered, mixed with Ecoscint (4 ml) and the radioactivity therein
determined by liquid scintillation. Under these conditions, using
yeast homogenates, control and blank values were 1078632 and
410619 dpm, respectively (values from four experiments,
mean6SEM).
Data Analysis
GraphPad PRISM (version 4) was used to analyze the data and
generate dose-response curves.
Supporting Information
Figure S1 Genetic Modification of PEA Production and
Inactivation in Yeast
Found at: doi:10.1371/journal.pone.0005942.s001 (0.01 MB
PDF)
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